JP2025065351A5 - - Google Patents

Download PDF

Info

Publication number
JP2025065351A5
JP2025065351A5 JP2025018512A JP2025018512A JP2025065351A5 JP 2025065351 A5 JP2025065351 A5 JP 2025065351A5 JP 2025018512 A JP2025018512 A JP 2025018512A JP 2025018512 A JP2025018512 A JP 2025018512A JP 2025065351 A5 JP2025065351 A5 JP 2025065351A5
Authority
JP
Japan
Prior art keywords
isolated
composition
box
high mobility
modified high
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025018512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025065351A (ja
Filing date
Publication date
Priority claimed from JP2019550715A external-priority patent/JP7596069B2/ja
Application filed filed Critical
Publication of JP2025065351A publication Critical patent/JP2025065351A/ja
Publication of JP2025065351A5 publication Critical patent/JP2025065351A5/ja
Priority to JP2025119036A priority Critical patent/JP2025148518A/ja
Pending legal-status Critical Current

Links

JP2025018512A 2017-03-15 2025-02-06 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 Pending JP2025065351A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025119036A JP2025148518A (ja) 2017-03-15 2025-07-15 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471834P 2017-03-15 2017-03-15
US62/471,834 2017-03-15
JP2019550715A JP7596069B2 (ja) 2017-03-15 2018-03-14 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
PCT/US2018/022508 WO2018170178A1 (en) 2017-03-15 2018-03-14 Composition and methods for disruption of bacterial biofilms without accompanying inflammation
JP2022194227A JP2023014389A (ja) 2017-03-15 2022-12-05 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022194227A Division JP2023014389A (ja) 2017-03-15 2022-12-05 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025119036A Division JP2025148518A (ja) 2017-03-15 2025-07-15 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2025065351A JP2025065351A (ja) 2025-04-17
JP2025065351A5 true JP2025065351A5 (https=) 2025-07-07

Family

ID=62025942

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019550715A Active JP7596069B2 (ja) 2017-03-15 2018-03-14 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
JP2022194227A Pending JP2023014389A (ja) 2017-03-15 2022-12-05 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
JP2025018512A Pending JP2025065351A (ja) 2017-03-15 2025-02-06 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
JP2025119036A Pending JP2025148518A (ja) 2017-03-15 2025-07-15 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019550715A Active JP7596069B2 (ja) 2017-03-15 2018-03-14 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
JP2022194227A Pending JP2023014389A (ja) 2017-03-15 2022-12-05 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025119036A Pending JP2025148518A (ja) 2017-03-15 2025-07-15 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法

Country Status (6)

Country Link
US (1) US11746136B2 (https=)
EP (1) EP3595445B1 (https=)
JP (4) JP7596069B2 (https=)
AU (1) AU2018236271B2 (https=)
CA (1) CA3056088A1 (https=)
WO (1) WO2018170178A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
JP7661008B2 (ja) 2017-01-04 2025-04-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
WO2018170178A1 (en) * 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2019354829B2 (en) * 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
EP4615483A2 (en) * 2022-11-11 2025-09-17 Research Institute at Nationwide Children's Hospital Compositions and methods for treating biofilms and neutrophil extracellular trap formation

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US20050131222A1 (en) 1995-04-21 2005-06-16 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20020132753A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CN100447154C (zh) 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
AU2002328203C1 (en) 2001-08-24 2009-01-08 Migenix Inc. Antimicrobial and anti-inflammatory peptides
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20030099602A1 (en) 2001-10-25 2003-05-29 Levin Gilbert V. D-tagatose as an anti-biofilm agent
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
JP2006510619A (ja) 2002-11-20 2006-03-30 クリティカル セラピューティクス,インコーポレイテッド 抗炎症剤としてのhmgb断片の使用
US20060121047A1 (en) 2002-11-20 2006-06-08 Tracey Kevin J Use of hmgb polypetides for increasing immune responses
WO2004061456A2 (de) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
US7297340B2 (en) 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
WO2004072094A2 (en) 2003-02-14 2004-08-26 Fondazione Centro San Raffaele Del Monte Tabor Hmgb1 modulator binding domain
CA2796381A1 (en) 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US20090029929A1 (en) 2004-03-26 2009-01-29 Locomogene, Inc. Decoy Nucleic Acid to Synoviolin Gene Promoter
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
US20060030539A1 (en) 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
US20060228384A1 (en) 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
CA2660668C (en) 2006-08-21 2016-06-28 The University Of British Columbia Small cationic antimicrobial peptides
EP1980269A1 (en) 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prevention of staphylococcus biofilm formation
CN103097399A (zh) 2010-03-29 2013-05-08 南加利福尼亚大学 用于去除生物膜的组合物及方法
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
ES2661500T3 (es) 2012-07-26 2018-04-02 Ospedale San Raffaele S.R.L. Variantes de HMGB1 y sus usos
ES2746971T3 (es) 2013-06-13 2020-03-09 Res Inst Nationwide Childrens Hospital Composiciones y procedimientos para el tratamiento de infecciones por burkholderia
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
GB201508337D0 (en) * 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
WO2018170178A1 (en) * 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
MX2020014006A (es) 2018-06-29 2021-05-27 Res Inst Nationwide Childrens Hospital Composiciones y métodos para mediar la eps.
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms

Similar Documents

Publication Publication Date Title
JP2025065351A5 (https=)
US6130045A (en) Thermostable polymerase
JP2024009014A5 (https=)
Uchimura et al. Cloning and sequencing of alginate lyase genes from deep-sea strains of Vibrio and Agarivorans and characterization of a new Vibrio enzyme
JP2009521932A5 (https=)
JP2020513808A5 (https=)
JP2009542219A5 (https=)
CN114606215B (zh) 一种真核生物来源的Argonaute蛋白及其应用
WO2025251550A1 (zh) 具有广谱裂解活性的肽聚糖水解酶LysPH1及其突变体和应用
JP2022504139A5 (https=)
CN116355887A (zh) 一种链球菌前噬菌体裂解酶lys733及其应用
WO2024131837A1 (en) Engineered nuclease with high salt tolerance
CN115820608B (zh) λ-卡拉胶酶突变体OUC-CglA-DPQQ及其应用
JP7022819B2 (ja) トランスアミナーゼ突然変異体及びその使用
CN102164950A (zh) 新型毒素-抗毒素系统
Thomas et al. Mycoplasma bovis shares insertion sequences with Mycoplasma agalactiae and Mycoplasma mycoides subsp. mycoides SC: Evolutionary and developmental aspects
JPH05328975A (ja) E1a−f遺伝子
DK2718430T3 (en) Technically designed sequence-specific ribonuclease H AND METHOD FOR ESTABLISHING SEKVENSPREFERENCEN OF DNA-RNA hybrid binding proteins
CN101186916A (zh) 一种编码双齿围沙蚕半胱氨酸蛋白酶抑制剂的基因序列及其氨基酸序列与应用
US20230235306A1 (en) Argonaute protein from eukaryotes and application thereof
BR0207284A (pt) Sequências de nucleotìdeo as quais codificam o gene rpsl
Hou et al. cDNA cloning and overexpression of ribosomal protein S19 gene (RPS19) from the Giant Panda
CN102747060A (zh) D-氨甲酰水解酶的突变体及其制备方法和应用
JP4982516B2 (ja) 塩耐性l−ミオイノシトール−1−ホスフェートシンターゼ及びそれを得る方法
Matthijs et al. The trehalose operon of Pseudomonas fluorescens ATCC 17400